Summary
DexCom, Inc. (DXCM) reported its financial results for the third quarter and first nine months ended September 30, 2016. The company demonstrated significant revenue growth year-over-year, with total revenue increasing by 43.4% to $148.6 million for the third quarter and by 51.3% to $402.1 million for the first nine months. This growth was primarily driven by increased sales volume of disposable sensors and durable systems for their G4 PLATINUM and G5 Mobile continuous glucose monitoring (CGM) systems. Despite strong revenue performance, the company continued to operate at a net loss, reporting a net loss of $18.8 million for the third quarter and $58.2 million for the first nine months. However, cash flow from operations remained positive and showed an increase compared to the prior year, indicating improving operational efficiency in managing working capital and non-cash expenses like share-based compensation. The company also highlighted its growing cash reserves and ample working capital, positioning it to fund operations and growth initiatives through at least September 30, 2017, supported by a new $200 million credit facility. Key strategic developments include ongoing product innovation with the G5 Mobile system and expansion of international operations. The company is actively managing its product pipeline and collaborations, including the significant partnership with Verily Life Sciences. DexCom's balance sheet shows a growing asset base, with an increase in cash and a substantial rise in property and equipment, net, reflecting investments in manufacturing capabilities. While gross profit margins remain healthy, the company continues to invest heavily in selling, general, and administrative expenses to support its growth and commercialization efforts. Investors should monitor the company's path to profitability, continued revenue acceleration, and its ability to effectively manage operating expenses and regulatory requirements in the expanding CGM market.
Financial Highlights
49 data points| Revenue | $148.60M |
| Cost of Revenue | $47.50M |
| Gross Profit | $101.10M |
| R&D Expenses | $43.90M |
| SG&A Expenses | $75.70M |
| Operating Expenses | $119.60M |
| Operating Income | -$18.50M |
| Interest Expense | $200K |
| Net Income | -$18.80M |
| EPS (Basic) | $-0.06 |
| Shares Outstanding (Basic) | 336.40M |
Key Highlights
- 1Total revenue increased by 43.4% to $148.6 million for the three months ended September 30, 2016, compared to $105.2 million in the prior year period.
- 2Revenue for the nine months ended September 30, 2016, increased by 51.3% to $402.1 million, up from $271.2 million in the prior year period.
- 3Gross profit increased to $101.1 million for the third quarter of 2016, an improvement from $74.7 million in the third quarter of 2015.
- 4The company reported a net loss of $18.8 million for the third quarter of 2016, a reduction from the $42.5 million net loss in the same period of 2015.
- 5Net cash provided by operating activities increased to $42.9 million for the nine months ended September 30, 2016, up from $37.7 million for the same period in 2015.
- 6As of September 30, 2016, cash and cash equivalents and marketable securities totaled $127.3 million, with working capital of $172.5 million, providing sufficient resources to fund operations through at least September 30, 2017.
- 7The company entered into a $200.0 million revolving credit agreement in June 2016, providing additional financial flexibility.